688336 logo

Sunshine Guojian Pharmaceutical (Shanghai) XSSC:688336 Stock Report

Last Price

CN¥21.60

Market Cap

CN¥13.3b

7D

-1.0%

1Y

-0.6%

Updated

24 Dec, 2024

Data

Company Financials +

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd

XSSC:688336 Stock Report

Market Cap: CN¥13.3b

688336 Stock Overview

A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of antibody drugs in China. More details

688336 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth1/6
Past Performance4/6
Financial Health5/6
Dividends2/6

My Notes

Capture your thoughts, links and company narrative

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd Competitors

Price History & Performance

Summary of share price highs, lows and changes for Sunshine Guojian Pharmaceutical (Shanghai)
Historical stock prices
Current Share PriceCN¥21.60
52 Week HighCN¥26.78
52 Week LowCN¥15.22
Beta0.39
1 Month Change-3.57%
3 Month Change25.58%
1 Year Change-0.60%
3 Year Changen/a
5 Year Changen/a
Change since IPO28.57%

Recent News & Updates

Recent updates

Shareholder Returns

688336CN BiotechsCN Market
7D-1.0%-3.0%-2.1%
1Y-0.6%-19.0%9.8%

Return vs Industry: 688336 exceeded the CN Biotechs industry which returned -19% over the past year.

Return vs Market: 688336 underperformed the CN Market which returned 9.8% over the past year.

Price Volatility

Is 688336's price volatile compared to industry and market?
688336 volatility
688336 Average Weekly Movement8.3%
Biotechs Industry Average Movement8.9%
Market Average Movement8.8%
10% most volatile stocks in CN Market13.0%
10% least volatile stocks in CN Market5.8%

Stable Share Price: 688336 has not had significant price volatility in the past 3 months compared to the CN market.

Volatility Over Time: 688336's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2002964n/awww.3s-guojian.com

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of antibody drugs in China. Its products include YISAIPU, a tumor necrosis factor inhibitor type II-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Septin, an initututab for injection; and Xenipax, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation, as well as used in conjunction with conventional immunosuppression regimens to increase the survival rate of transplanted organs and enhance patients' quality of life. The company is also developing products for autoimmune, oncology, ophthalmological, and other diseases.

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd Fundamentals Summary

How do Sunshine Guojian Pharmaceutical (Shanghai)'s earnings and revenue compare to its market cap?
688336 fundamental statistics
Market capCN¥13.32b
Earnings (TTM)CN¥363.75m
Revenue (TTM)CN¥1.22b

36.6x

P/E Ratio

10.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
688336 income statement (TTM)
RevenueCN¥1.22b
Cost of RevenueCN¥286.11m
Gross ProfitCN¥936.73m
Other ExpensesCN¥572.98m
EarningsCN¥363.75m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.59
Gross Margin76.60%
Net Profit Margin29.75%
Debt/Equity Ratio1.0%

How did 688336 perform over the long term?

See historical performance and comparison

Dividends

0.3%

Current Dividend Yield

14%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 22:35
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wen DaiHuatai Research
Yuan Yuan SunIndustrial Securities Co. Ltd.
Ban WangMinsheng Securities Co.